{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T05:01:37Z","timestamp":1789275697577,"version":"build-2803163510"},"reference-count":209,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"am","delay-in-days":362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Airc Italian Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["1357-19"],"award-info":[{"award-number":["1357-19"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.blre.2023.101072","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T16:08:35Z","timestamp":1678550915000},"page":"101072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Current landscape of translational and clinical research in myelodysplastic syndromes\/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)"],"prefix":"10.1016","volume":"60","author":[{"given":"Jan Philipp","family":"Bewersdorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoer","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Bejar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Borate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Boultwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Buckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hetty E.","family":"Carraway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane E.","family":"Churpek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval G.","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo Giovanni Della","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"DeZern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Halene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Hasserjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Hourigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Kon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay K.","family":"Kuchroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan F.","family":"List","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Majeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olatoyosi","family":"Odenike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail J.","family":"Roboz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Sallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkael A.","family":"Sekeres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T.","family":"Starczynowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Steensma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abdel-Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina L.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Savona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2023.101072_bb0005","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of Haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia."},{"issue":"11","key":"10.1016\/j.blre.2023.101072_bb0010","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute Leukemia: integrating morphological, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101072_bb0015","first-page":"JCO1901823","article-title":"Integrating the \u201cImmunome\u201d in the stratification of myelodysplastic syndromes and future clinical trial design","author":"Winter","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101072_bb0020","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2018-10-844654","article-title":"The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes","volume":"133","author":"Sallman","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0025","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.blre.2023.101072_bb0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2023.101072_bb0035","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0040","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood.2020004850","article-title":"SF3B1-mutant MDS as a distinct disease subtype: a proposal from the international working Group for the Prognosis of MDS","volume":"136","author":"Malcovati","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0045","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.20.02810","article-title":"Personalized prediction model to risk stratify patients with myelodysplastic syndromes","volume":"39","author":"Nazha","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101072_bb0050","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2023.101072_bb0055","doi-asserted-by":"crossref","first-page":"106","DOI":"10.6004\/jnccn.2022.0009","article-title":"NCCN guidelines\u00ae insights: myelodysplastic syndromes, version 3.2022","volume":"20","author":"Greenberg","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.blre.2023.101072_bb0060","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1904794","article-title":"Myelodysplastic syndromes","volume":"383","author":"Cazzola","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101072_bb0065","article-title":"The coming of age of preclinical models of MDS","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2023.101072_bb0070","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood.2021015162","article-title":"Inflammation and myeloid malignancy: quenching the flame","volume":"140","author":"Stubbins","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0075","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41467-018-08166-x","article-title":"A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies","volume":"10","author":"Song","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2023.101072_bb0080","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/nm.4103","article-title":"A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells","volume":"22","author":"Reinisch","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2023.101072_bb0085","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.stem.2014.02.014","article-title":"Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit","volume":"14","author":"Medyouf","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2023.101072_bb0090","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3324\/haematol.2010.027557","article-title":"Establishment of a xenograft model of human myelodysplastic syndromes","volume":"96","author":"Muguruma","year":"2011","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2023.101072_bb0095","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1126\/science.abe2485","article-title":"Combined liver-cytokine humanization comes to the rescue of circulating human red blood cells","volume":"371","author":"Song","year":"2021","journal-title":"Science."},{"key":"10.1016\/j.blre.2023.101072_bb0100","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101072_bb0105","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101072_bb0110","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature."},{"issue":"12","key":"10.1016\/j.blre.2023.101072_bb0115","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1038\/s41375-022-01724-9","article-title":"Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the international workshop for myelodysplastic syndromes","volume":"36","author":"Zeidan","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2023.101072_bb0120","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0125","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2023.101072_bb0130","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101072_bb0135","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0140","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.20.01659","article-title":"Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes","volume":"39","author":"Bersanelli","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2023.101072_bb0145","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41375-022-01766-z","article-title":"Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy","volume":"37","author":"Zeidan","year":"2023","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2023.101072_bb0150","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood-2022-162913","article-title":"A clinically practicable approach to predict TP53 allelic configurations in myeloid neoplasia","volume":"140","author":"Bahaj","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0155","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41375-018-0351-2","article-title":"TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups","volume":"33","author":"Haase","year":"2019","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2023.101072_bb0160","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood.2019000942","article-title":"Genetics of progression from MDS to secondary leukemia","volume":"136","author":"Menssen","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0165","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2018.09.001","article-title":"Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it","volume":"34","author":"Zeidan","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2023.101072_bb0175","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/bloodadvances.2017013037","article-title":"Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies","volume":"2","author":"Drazer","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101072_bb0180","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41568-020-00315-z","article-title":"Advances in germline predisposition to acute leukaemias and myeloid neoplasms","volume":"21","author":"Klco","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.blre.2023.101072_bb0185","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1038\/s41375-021-01137-0","article-title":"Germline variants drive myelodysplastic syndrome in young adults","volume":"35","author":"Feurstein","year":"2021","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2023.101072_bb0190","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ccell.2015.03.017","article-title":"Inherited and somatic defects in DDX41 in myeloid neoplasms","volume":"27","author":"Polprasert","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2023.101072_bb0195","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2015-05-647172","article-title":"Disease evolution and outcomes in familial AML with germline CEBPA mutations","volume":"126","author":"Tawana","year":"2015","journal-title":"Blood."},{"issue":"24","key":"10.1016\/j.blre.2023.101072_bb0200","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood.2022015790","article-title":"Germline predisposition variants occur in myelodysplastic syndrome patients of all ages","volume":"140","author":"Feurstein","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0205","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.19.02960","article-title":"Germline and somatic tumor testing in epithelial ovarian Cancer: ASCO guideline","volume":"38","author":"Konstantinopoulos","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101072_bb0210","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41467-020-14829-5","article-title":"The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants","volume":"11","author":"Rio-Machin","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2023.101072_bb0215","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0220","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2023.101072_bb0225","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101072_bb0230","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101072_bb0235","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/blood.2021013531","article-title":"Association of clonal hematopoiesis with chronic obstructive pulmonary disease","volume":"139","author":"Miller","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0240","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal Hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101072_bb0245","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1182\/blood-2015-10-672659","article-title":"Cytopenias + mutations - dysplasia = what?","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100587","article-title":"From clonal hematopoiesis to myeloid leukemia and what happens in between: will improved understanding lead to new therapeutic and preventive opportunities?","volume":"37","author":"Bewersdorf","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2023.101072_bb0255","article-title":"ICUS, IDUS, CHIP and CCUS: diagnostic criteria, Separation from MDS and clinical implications","volume":"1-9","author":"Valent","year":"2018","journal-title":"Pathobiology."},{"key":"10.1016\/j.blre.2023.101072_bb0260","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0265","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1182\/bloodadvances.2018020222","article-title":"Clinical consequences of clonal hematopoiesis of indeterminate potential","volume":"2","author":"Steensma","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101072_bb0270","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41586-022-04785-z","article-title":"The longitudinal dynamics and natural history of clonal haematopoiesis","volume":"606","author":"Fabre","year":"2022","journal-title":"Nature."},{"key":"10.1016\/j.blre.2023.101072_bb0275","first-page":"1161","article-title":"Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals","volume":"135","author":"van Zeventer","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0280","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","article-title":"Somatic mutations precede acute myeloid leukemia years before diagnosis","volume":"24","author":"Desai","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2023.101072_bb0285","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2017-01-764951","article-title":"Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias","volume":"130","author":"Gibson","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0290","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2023.101072_bb0295","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1182\/blood-2018-99-119530","article-title":"Oncologic therapy for solid Tumors alters the risk of clonal Hematopoiesis","volume":"132","author":"Bolton","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0300","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal Hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101072_bb0305","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1470-2045(16)30627-1","article-title":"Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study","volume":"18","author":"Gillis","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2023.101072_bb0310","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1001\/jamaoncol.2021.4664","article-title":"Preexisting TP53-variant clonal Hematopoiesis and risk of secondary myeloid neoplasms in patients with high-grade ovarian cancer treated with Rucaparib","volume":"7","author":"Kwan","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.blre.2023.101072_bb0315","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1182\/blood-2022-165163","article-title":"Phase II study assessing safety and preliminary efficacy of high dose intravenous ascorbic acid in patients with TET2 mutant clonal Cytopenias of undetermined significance","volume":"140","author":"Xie","year":"2022","journal-title":"Blood."},{"issue":"24","key":"10.1016\/j.blre.2023.101072_bb0320","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.2020006158","article-title":"TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype","volume":"136","author":"Sallman","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101072_bb0325","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/s41375-019-0645-z","article-title":"Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents","volume":"34","author":"Kubasch","year":"2020","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2023.101072_bb0330","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1158\/1078-0432.CCR-17-3763","article-title":"A multi-center phase I trial of Ipilimumab in patients with myelodysplastic syndromes following Hypomethylating agent failure","volume":"24","author":"Zeidan","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2023.101072_bb0335","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2021005487","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.blre.2023.101072_bb0340","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/bjh.17689","article-title":"Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome","volume":"195","author":"Chien","year":"2021","journal-title":"Br J Haematol."},{"key":"10.1016\/j.blre.2023.101072_bb0345","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41573-022-00493-5","article-title":"Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities","volume":"21","author":"Kim","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.blre.2023.101072_bb0350","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","article-title":"Venetoclax increases Intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade","volume":"11","author":"Kohlhapp","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2023.101072_bb0355","article-title":"Immune checkpoint inhibition in myeloid malignancies: moving beyond the PD-1\/PD-L1 and CTLA-4 pathways","volume":"100709","author":"Bewersdorf","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2023.101072_bb0360","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2023.101072_bb0365","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.blre.2023.101072_bb0370","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/nm.2871","article-title":"Bat3 promotes T cell responses and autoimmunity by repressing Tim-3\u2013mediated cell death and exhaustion","volume":"18","author":"Rangachari","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2023.101072_bb0375","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/blood-2008-10-185884","article-title":"Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation","volume":"113","author":"Nakayama","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0380","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat Immunol"},{"key":"10.1016\/j.blre.2023.101072_bb0385","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","article-title":"TIM-3 is a promising target to selectively kill acute myeloid Leukemia stem cells","volume":"7","author":"Kikushige","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2023.101072_bb0390","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.stem.2015.07.011","article-title":"A TIM-3\/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid Leukemia stem cells and leukemic progression","volume":"17","author":"Kikushige","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2023.101072_bb0395","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood-2021-146039","article-title":"Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High\/High-Risk Myelodysplastic Syndrome (vHR\/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study","volume":"138","author":"Brunner","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101072_bb0400","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1182\/blood-2022-158612","article-title":"Primary results of Stimulus-MDS1: A randomized, double-blind, placebo-controlled phase II study of TIM-3 inhibition with Sabatolimab added to Hypomethylating agents (HMAs) in adult patients with higher-risk myelodysplastic syndromes (MDS)","volume":"140","author":"Zeidan","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0405","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-134718","article-title":"The STIMULUS program: clinical trials evaluating Sabatolimab (MBG453) combination therapy in patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) or acute myeloid Leukemia (AML)","volume":"136","author":"Zeidan","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0410","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3389\/fonc.2019.01380","article-title":"Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies","volume":"9","author":"Chao","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2023.101072_bb0415","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell."},{"key":"10.1016\/j.blre.2023.101072_bb0420","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.leukres.2013.04.008","article-title":"CD47 is expressed abnormally on hematopoietic cells in myelodysplastic syndrome","volume":"37","author":"Jiang","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2023.101072_bb0425","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1073\/pnas.1222861110","article-title":"Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes","volume":"110","author":"Pang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2023.101072_bb0430","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/01.HS9.0000843556.59348.1d","article-title":"S166: Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1B study results","volume":"6","author":"Sallman","year":"2022","journal-title":"HemaSphere."},{"key":"10.1016\/j.blre.2023.101072_bb0435","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2022-170188","article-title":"Phase I\/II study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in patients (pts) with newly diagnosed (ND) older\/unfit or high-risk acute myeloid Leukemia (AML) and relapsed\/refractory (R\/R) AML","volume":"140","author":"Daver","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201832","article-title":"ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile","volume":"13","author":"Kauder","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2023.101072_bb0445","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(21)00584-2","article-title":"Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study","volume":"22","author":"Lakhani","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2023.101072_bb0450","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1182\/blood-2021-146547","article-title":"Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 \/ 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02)","volume":"138","author":"Garcia-Manero","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101072_bb0455","doi-asserted-by":"crossref","first-page":"9046","DOI":"10.1182\/blood-2022-157606","article-title":"Evorpacept (ALX148), a CD47-blocking myeloid checkpoint inhibitor, in combination with Azacitidine and Venetoclax in patients with acute myeloid Leukemia (ASPEN-05): results from phase 1a dose escalation part","volume":"140","author":"Garcia-Manero","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0460","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2023.101072_bb0465","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1469594","article-title":"VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.blre.2023.101072_bb0470","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.862757","article-title":"Distinct immune stimulatory effects of anti-human VISTA antibodies are determined by fc-receptor interaction","volume":"13","author":"Mostb\u00f6ck","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2023.101072_bb0475","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1182\/blood-2022-158314","article-title":"Programmed Death-1 homolog (PD-1H\/VISTA) blockade confers a synergistic anti-Leukemia effect with PD-1 blockade","volume":"140","author":"Kim","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0480","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1158\/1078-0432.CCR-17-2542","article-title":"Spatially resolved and quantitative analysis of VISTA\/PD-1H as a novel immunotherapy target in human non-small cell lung cancer","volume":"24","author":"Villarroel-Espindola","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2023.101072_bb0485","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm.4308","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2023.101072_bb0490","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3324\/haematol.2019.219345","article-title":"Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis","volume":"105","author":"Stahl","year":"2020","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2023.101072_bb0495","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1200\/JCO.2010.31.2686","article-title":"Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33\/99","volume":"29","author":"Passweg","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101072_bb0500","first-page":"3591","article-title":"VEXAS syndrome","volume":"137","author":"Grayson","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0505","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjh.17893","article-title":"Azacitidine for patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry","volume":"196","author":"Comont","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101072_bb0510","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1038\/s41375-022-01698-8","article-title":"A phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune\/inflammatory disorders and VEXAS syndrome associated with MDS and CMML","volume":"36","author":"Mekinian","year":"2022","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2023.101072_bb0515","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1158\/2159-8290.CD-21-1146","article-title":"The impact of inflammation-induced tumor plasticity during myeloid transformation","volume":"12","author":"Yeaton","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2023.101072_bb0520","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.blre.2023.101072_bb0525","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MOH.0000000000000693","article-title":"IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies","volume":"29","author":"Bennett","year":"2022","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.blre.2023.101072_bb0530","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201544","article-title":"Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS","volume":"218","author":"Trowbridge","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2023.101072_bb0535","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41556-019-0314-5","article-title":"U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies","volume":"21","author":"Smith","year":"2019","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.blre.2023.101072_bb0540","first-page":"11","article-title":"Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations","author":"Choudhary","year":"2022","journal-title":"Elife."},{"key":"10.1016\/j.blre.2023.101072_bb0545","first-page":"7","article-title":"Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS\/STING\/NLRP3 axis in myelodysplastic syndromes. JCI","author":"McLemore","year":"2022","journal-title":"Insight."},{"key":"10.1016\/j.blre.2023.101072_bb0550","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1200\/JCO.2022.40.16_suppl.7016","article-title":"Phase 1\/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed\/refractory (R\/R) acute myeloid leukemia or lyelodysplastic syndrome","volume":"40","author":"Garcia-Manero","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101072_bb0555","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1158\/0008-5472.CAN-21-3503","article-title":"Epigenetic and transcriptional regulation of innate immunity in cancer","volume":"82","author":"Chen","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2023.101072_bb0560","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/s41467-022-29668-9","article-title":"Allogeneic TCR\u03b1\u03b2 deficient CAR T-cells targeting CD123 in acute myeloid leukemia","volume":"13","author":"Sugita","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2023.101072_bb0565","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1200\/JCO.2020.38.15_suppl.7508","article-title":"Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML)","volume":"38","author":"Ravandi","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101072_bb0570","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2019-127977","article-title":"Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33\/CD3 BiTE\u00ae (Bispecific T-Cell Engager) in Patients with Relapsed\/Refractory (R\/R) Acute Myeloid Leukemia (AML)","volume":"134","author":"Subklewe","year":"2019","journal-title":"Blood"},{"issue":"1521\u201338","key":"10.1016\/j.blre.2023.101072_bb0575","article-title":"Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis","volume":"185","author":"Pan","year":"2022","journal-title":"Cell."},{"key":"10.1016\/j.blre.2023.101072_bb0580","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.blre.2023.101072_bb0585","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.2022016963","article-title":"Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy","volume":"140","author":"Wei","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0590","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2012-05-430736","article-title":"Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome","volume":"120","author":"Slape","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0595","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2021-145613","article-title":"Molecular responses are observed across mutational Spectrum in treatment-Na\u00efve higher-risk myelodysplastic syndrome patients treated with Venetoclax plus Azacitidine","volume":"138","author":"Garcia","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0600","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood-2020-139492","article-title":"Safety, efficacy, and patient-reported outcomes of Venetoclax in combination with Azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase 1b study","volume":"136","author":"Garcia","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(22)00216-2","article-title":"Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-Centre, dose-escalation, dose-expansion, phase 1-2 study","volume":"9","author":"Bazinet","year":"2022","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101072_bb0610","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ajh.26771","article-title":"A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes","volume":"98","author":"Zeidan","year":"2023","journal-title":"Am J Hematol."},{"key":"10.1016\/j.blre.2023.101072_bb0615","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1182\/blood.2019004262","article-title":"Epigenetic deregulation in myeloid malignancies","volume":"138","author":"Huang","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0620","doi-asserted-by":"crossref","DOI":"10.1177\/2040620718816698","article-title":"Epigenetic therapy combinations in acute myeloid leukemia: what are the options?","volume":"10","author":"Bewersdorf","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2023.101072_bb0625","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1182\/blood-2009-01-200519","article-title":"MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation","volume":"114","author":"Figueroa","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0630","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3109\/10428194.2013.855309","article-title":"Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents","volume":"55","author":"DiNardo","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2023.101072_bb0635","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1200\/JCO.2013.50.3102","article-title":"Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia intergroup trial E1905","volume":"32","author":"Prebet","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101072_bb0640","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/2159-8290.CD-16-1032","article-title":"Epigenetic identity in AML depends on disruption of nonpromoter regulatory elements and is affected by antagonistic effects of mutations in epigenetic modifiers","volume":"7","author":"Glass","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2023.101072_bb0645","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.1038\/s41467-022-34211-x","article-title":"MIR retrotransposons link the epigenome and the transcriptome of coding genes in acute myeloid leukemia","volume":"13","author":"Telonis","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2023.101072_bb0650","doi-asserted-by":"crossref","first-page":"9769","DOI":"10.1182\/blood-2022-163704","article-title":"DNA methylation profiles capture clinical and molecular heterogeneity of MDS and can be harnessed for the development of robust biomarkers predictive of response to Azacitidine","volume":"140","author":"Yang","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0655","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1172\/JCI78752","article-title":"Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia","volume":"125","author":"Meldi","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2023.101072_bb0660","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101072_bb0665","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ng.1009","article-title":"Dnmt3a is essential for hematopoietic stem cell differentiation","volume":"44","author":"Challen","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2023.101072_bb0670","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.celrep.2018.03.025","article-title":"Loss of Dnmt3a immortalizes hematopoietic stem cells in vivo","volume":"23","author":"Jeong","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.blre.2023.101072_bb0675","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.ccell.2016.05.003","article-title":"DNMT3A loss drives enhancer Hypomethylation in FLT3-ITD-associated Leukemias","volume":"29","author":"Yang","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2023.101072_bb0680","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature09586","article-title":"Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2","volume":"468","author":"Ko","year":"2010","journal-title":"Nature."},{"key":"10.1016\/j.blre.2023.101072_bb0685","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation","volume":"20","author":"Moran-Crusio","year":"2011","journal-title":"Cancer Cell"},{"issue":"1079\u201395","key":"10.1016\/j.blre.2023.101072_bb0690","article-title":"Restoration of TET2 function blocks aberrant self-renewal and Leukemia progression","volume":"170","author":"Cimmino","year":"2017","journal-title":"Cell."},{"key":"10.1016\/j.blre.2023.101072_bb0695","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3324\/haematol.2010.025494","article-title":"IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis","volume":"95","author":"Thol","year":"2010","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2023.101072_bb0700","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1084\/jem.20092506","article-title":"Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations","volume":"207","author":"Gross","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2023.101072_bb0705","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature."},{"key":"10.1016\/j.blre.2023.101072_bb0710","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0715","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and Azacitidine in IDH1-mutated acute myeloid Leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101072_bb0720","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101072_bb0725","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.1200\/JCO.2022.40.16_suppl.7053","article-title":"Ivosidenib in patients with IDH1-mutant relapsed\/refractory myelodysplastic syndrome (R\/R MDS): updated enrollment and results of a phase 1 dose-escalation and expansion substudy","volume":"40","author":"Sallman","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101072_bb0730","article-title":"Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome","author":"DiNardo","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.blre.2023.101072_bb0735","unstructured":"Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1\/2 trial. Lancet Haematol."},{"issue":"643\u201358","key":"10.1016\/j.blre.2023.101072_bb0740","article-title":"HOXA9 reprograms the enhancer landscape to promote Leukemogenesis","volume":"34","author":"Sun","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2023.101072_bb0745","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ccr.2011.06.010","article-title":"MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L","volume":"20","author":"Bernt","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2023.101072_bb0750","doi-asserted-by":"crossref","first-page":"7288","DOI":"10.1038\/s41598-021-86646-9","article-title":"DOT1L inhibitors block abnormal self-renewal induced by cohesin loss","volume":"11","author":"Heimbruch","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2023.101072_bb0755","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2015-11-684225","article-title":"DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia","volume":"128","author":"Rau","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0760","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0765","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1101\/gad.349368.122","article-title":"Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic","volume":"36","author":"Bewersdorf","year":"2022","journal-title":"Genes Dev"},{"issue":"660\u201373","key":"10.1016\/j.blre.2023.101072_bb0770","article-title":"A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged Leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2023.101072_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105335","article-title":"Targeting LSD1 for acute myeloid leukemia (AML) treatment","volume":"164","author":"Zhang","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.blre.2023.101072_bb0780","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.molcel.2007.06.039","article-title":"Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1","volume":"27","author":"Saleque","year":"2007","journal-title":"Mol Cell"},{"key":"10.1016\/j.blre.2023.101072_bb0785","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1182\/blood-2017-09-807024","article-title":"LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C\/EBPalpha-dependent enhancers in AML","volume":"131","author":"Cusan","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0790","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/s41375-018-0375-7","article-title":"LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML","volume":"33","author":"Barth","year":"2019","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2023.101072_bb0795","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/bloodadvances.2020003521","article-title":"LSD1 defines erythroleukemia metabolism by controlling the lineage-specific transcription factors GATA1 and C\/EBP\u03b1","volume":"5","author":"Kohrogi","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101072_bb0800","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood-2018-99-115411","article-title":"The Lysine-Specific Demethylase 1 (LSD1) Inhibitor Tranylcypromine (TCP) in Combination with ATRA Is Tolerable and Has Anti-Leukemic Activity in Adult Patients with Relapsed\/Refractory AML and MDS","volume":"132","author":"Watts","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101072_bb0805","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1182\/blood-2021-146791","article-title":"Phase 1\/2 Study Investigating CC-90011, a Potent, Selective, and Reversible Oral Inhibitor of Lysine-Specific Demethylase 1 (LSD1), Plus Concurrent Venetoclax (VEN) and Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML)","volume":"138","author":"DiNardo","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101072_bb0810","doi-asserted-by":"crossref","first-page":"8388","DOI":"10.18632\/oncotarget.3460","article-title":"Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes","volume":"6","author":"Devillier","year":"2015","journal-title":"Oncotarget."},{"issue":"12","key":"10.1016\/j.blre.2023.101072_bb0815","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0820","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.1038\/ncomms8307","article-title":"Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex","volume":"6","author":"Balasubramani","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2023.101072_bb0825","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1038\/s41467-018-05085-9","article-title":"Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis","volume":"9","author":"Asada","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2023.101072_bb0830","first-page":"515","article-title":"Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia","volume":"2","author":"Wang","year":"2021","journal-title":"Nat Can"},{"key":"10.1016\/j.blre.2023.101072_bb0835","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41467-018-08255-x","article-title":"BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation","volume":"10","author":"Campagne","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2023.101072_bb0840","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41375-018-0198-6","article-title":"Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification","volume":"33","author":"Uni","year":"2019","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2023.101072_bb0845","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.20.01895","article-title":"Imetelstat achieves meaningful and durable transfusion Independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study","volume":"39","author":"Steensma","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101072_bb0850","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.leukres.2014.04.008","article-title":"Telomerase, hTERT and splice variants in patients with myelodysplastic syndromes","volume":"38","author":"Dong","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2023.101072_bb0855","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/bloodadvances.2018022012","article-title":"Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells","volume":"2","author":"Wang","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101072_bb0860","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1056\/NEJMoa1503479","article-title":"Telomerase inhibitor Imetelstat in patients with essential Thrombocythemia","volume":"373","author":"Baerlocher","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101072_bb0865","series-title":"Geron announces positive top-line results from IMerge phase 3 trial of Imetelstat in lower risk MDS","author":"Corporation","year":"2023"},{"key":"10.1016\/j.blre.2023.101072_bb0870","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1182\/blood.2019004260","article-title":"Splicing factor mutations in hematologic malignancies","volume":"138","author":"Chen","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0875","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood.V126.23.907.907","article-title":"Somatic mutations in MDS patients are associated with clinical features and predict prognosis independent of the IPSS-R: analysis of combined datasets from the international working Group for Prognosis in MDS-Molecular Committee","volume":"126","author":"Bejar","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0880","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/modpathol.2014.160","article-title":"Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations","volume":"28","author":"Ohgami","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.blre.2023.101072_bb0885","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","article-title":"Frequency and prognostic impact of mutations in <em>SRSF2<\/em>, <em>U2AF1<\/em>, and <em>ZRSR2<\/em> in patients with myelodysplastic syndromes","volume":"119","author":"Thol","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0890","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","article-title":"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia","volume":"127","author":"Nadeu","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0895","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.molmed.2021.04.005","article-title":"Therapeutic modulation of RNA splicing in malignant and non-malignant disease","volume":"27","author":"El Marabti","year":"2021","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.blre.2023.101072_bb0900","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm.4493","article-title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers","volume":"24","author":"Seiler","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2023.101072_bb0905","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1038\/s41375-021-01328-9","article-title":"Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms","volume":"35","author":"Steensma","year":"2021","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2023.101072_bb0910","doi-asserted-by":"crossref","first-page":"eaal3755","DOI":"10.1126\/science.aal3755","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15","volume":"356","author":"Han","year":"2017","journal-title":"Science."},{"key":"10.1016\/j.blre.2023.101072_bb0915","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1002\/cncr.31398","article-title":"Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"124","author":"Assi","year":"2018","journal-title":"Cancer."},{"key":"10.1016\/j.blre.2023.101072_bb0920","doi-asserted-by":"crossref","first-page":"9065","DOI":"10.1182\/blood-2022-156830","article-title":"A phase II clinical trial of E7820 for patients with relapsed\/refractory myeloid malignancies with mutations in splicing factor genes","volume":"140","author":"Bewersdorf","year":"2022","journal-title":"Blood."},{"issue":"4032\u201347","key":"10.1016\/j.blre.2023.101072_bb0925","article-title":"Pharmacologic modulation of RNA splicing enhances anti-tumor immunity","volume":"184","author":"Lu","year":"2021","journal-title":"Cell."},{"key":"10.1016\/j.blre.2023.101072_bb0930","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.3324\/haematol.2020.254193","article-title":"Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations","volume":"106","author":"Flach","year":"2021","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2023.101072_bb0935","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1038\/s41375-020-0753-9","article-title":"SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications","volume":"34","author":"Singh","year":"2020","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2023.101072_bb0940","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1158\/0008-5472.CAN-17-3970","article-title":"Spliceosome mutations induce R loop-associated sensitivity to ATR inhibition in myelodysplastic syndromes","volume":"78","author":"Nguyen","year":"2018","journal-title":"Cancer Res"},{"issue":"412\u201325","key":"10.1016\/j.blre.2023.101072_bb0945","article-title":"The augmented R-loop is a unifying mechanism for myelodysplastic syndromes induced by high-risk splicing factor mutations","volume":"69","author":"Chen","year":"2018","journal-title":"Mol Cell"},{"key":"10.1016\/j.blre.2023.101072_bb0950","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1038\/s41467-019-13001-y","article-title":"Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes","volume":"10","author":"Nagata","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2023.101072_bb0955","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1182\/blood.V128.22.1993.1993","article-title":"Clinicopathological features and mutational analysis of patients with aplastic Anemia and Hypoplastic myelodysplastic syndrome","volume":"128","author":"Zhang","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0960","article-title":"An agenda to advance research in MDS: a TOP 10 priority List from the first international workshop in MDS (iwMDS)","author":"Stahl","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.blre.2023.101072_bb0965","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022018604","article-title":"Consensus proposal for revised international working group response criteria for higher risk myelodysplastic syndromes","author":"Zeidan","year":"2023","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0970","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1080\/10428194.2020.1861267","article-title":"Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia","volume":"62","author":"Chen","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2023.101072_bb0975","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2021011304","article-title":"Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal","volume":"139","author":"Estey","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0980","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1182\/blood-2022-170158","article-title":"A product of \u201cclash of titans\u201d or true reflection of disease biology? Validation of 2022 WHO and ICC classifications in a large dataset of patients with myelodysplastic syndrome","volume":"140","author":"Ball","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb0985","article-title":"Deciphering <em>TP53<\/em> mutant cancer evolution with Single-Cell Multi-Omics","author":"Rodriguez-Meira","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.blre.2023.101072_bb0990","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2023.101072_bb0995","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature."},{"key":"10.1016\/j.blre.2023.101072_bb1000","first-page":"265","article-title":"Impact of conditioning intensity and genomics on relapse after allogeneic transplantation for patients with myelodysplastic syndrome. JCO precis","author":"Dillon","year":"2021","journal-title":"Oncol."},{"issue":"21","key":"10.1016\/j.blre.2023.101072_bb1005","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute Leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb1010","first-page":"JCO1800331","article-title":"Managing clonal hematopoiesis in patients with solid Tumors","author":"Bolton","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101072_bb1015","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb1020","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1182\/blood-2022-159388","article-title":"Interplay of TP53 allelic state, blast count and karyotype on survival of patients with AML and MDS","volume":"140","author":"Stengel","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb1025","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1182\/blood-2022-165257","article-title":"TP53 allelic state in myelodysplastic syndromes with 5q deletion","volume":"140","author":"G\u00f3mez","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101072_bb1030","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/bloodadvances.2021006138","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101072_bb1035","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and Azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101072_bb1040","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus Azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid Leukemia: a phase II study by the Groupe francophone des My\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101072_bb1045","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","article-title":"Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML","volume":"6","author":"Ad\u00e8s","year":"2022","journal-title":"Blood Adv"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:29:50Z","timestamp":1759436990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23000334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":209,"alternative-id":["S0268960X23000334"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101072","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current landscape of translational and clinical research in myelodysplastic syndromes\/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101072"}}